Drug_Name,STUDYID,YEAR,Country,Dataset,Patient_Count,Median_Age,Female_Percentage,Male_Percentage,Median_BMI,Smoking_History_Yes_Percentage,Total_ADL_Independence_Percentage,LHRH_Use_Percentage,Tumor_Stage_T1_Percentage,Tumor_Stage_T2_Percentage,Tumor_Stage_T3_Percentage,Tumor_Stage_T4_Percentage,Nodal_Stage_N0_Percentage,Nodal_Stage_N1_Percentage,Nodal_Stage_N2_Percentage,Nodal_Stage_N3_Percentage,Stage_I_Percentage,Stage_II_Percentage,Stage_III_Percentage,Diabetes_Mellitus_Percentage,Congestive_Heart_Failure_Percentage,Stroke_Percentage,Atrial_Fibrillation_Percentage,Myocardial_Infarction_Percentage,Neoadjuvant_Chemotherapy_Received_Percentage,Adjuvant_Chemotherapy_Received_Percentage,Postoperative_RT_Received_Percentage,Common_Neoadjuvant_Regimen_1,Common_Neoadjuvant_Regimen_2,Common_Adjuvant_Regimen_1,Common_Adjuvant_Regimen_2,Tamoxifen_Percentage,Letrozole_Percentage,Anastrozole_Percentage,Antidiarrheal_Agent_Probiotics_Percentage,Antiemetic_Agent_Percentage,Painkiller_Antipyretic_Percentage,Beds_Less_Than_200_Percentage,Beds_200_To_499_Percentage,Beds_Greater_Or_Equal_To_500_Percentage,Designated_Cancer_Hospital_Percentage,Months_Between_Surgery_And_Index_Date
Ixazomib,IXA2023-001,2023,USA,MDV,350,68,52,48,27.5,32,85,12,15,35,30,20,45,30,15,10,20,35,30,18,8,5,10,6,25,40,35,Docetaxel + Cisplatin + 5-FU,Paclitaxel + Carboplatin,AC (Doxorubicin + Cyclophosphamide),Taxol,22,18,20,30,60,45,15,45,40,60,2
Ixazomib,IXA2023-002,2023,Germany,Claim Database,420,72,48,52,26.8,38,78,15,12,38,32,18,42,32,16,10,18,38,32,22,10,7,12,8,28,42,30,"FEC (5-Fluorouracil, Epirubicin, Cyclophosphamide)",Docetaxel + Doxorubicin,"CMF (Cyclophosphamide, Methotrexate, 5-Fluorouracil)",Anthracycline-based therapy,25,20,15,35,65,50,20,50,30,55,3
Ixazomib,IXA2023-003,2023,Japan,MDV,280,65,55,45,24.5,25,90,10,20,40,25,15,50,28,12,10,25,40,25,15,6,4,8,5,22,38,40,S-1 + Docetaxel,Paclitaxel + Trastuzumab,Capecitabine,HER2 targeted therapy,20,15,25,25,55,40,10,40,50,70,1
